Evidence map›Paper›PMID 37178794›Full record

ArticleVirus research2023

SARS-CoV-2 omicron BA.1.1 is highly resistant to antibody neutralization of convalescent serum from the origin strain.

Jianhua Li, Xiaoyan Li, Haiyan Mao, Chen Huang, Yi Sun, Liangbin Miao, Jiaxuan Li, Wanchen Song, Yanjun Zhang, Jinsong Huang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virus research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jianhua LiZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Xiaoyan LiZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Haiyan MaoZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Chen HuangZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Yi SunZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Liangbin MiaoDepartment of Hepatology, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiaxuan LiShulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Wanchen SongSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China.
Yanjun ZhangZhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China. Electronic address: yjzhang@cdc.zj.cn.
Jinsong HuangDepartment of Hepatology, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: huangjinsongyz@126.com.
Keda ChenShulan International Medical College, Zhejiang Shuren University, Hangzhou, China. Electronic address: chenkd@zjsru.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence and rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (BA.1.1) has attracted global attention. The numerous mutations in the spike protein suggest that it may have altered susceptibility to immune protection elicited by the existing coronavirus disease 2019 (COVID-19) infection. We used a live virus neutralization test and SARS-CoV-2 pseudotype vesicular stomatitis virus vector-based neutralization assay to assess the degree of immune escape efficiency of the original, Delta (B1.617.2), and Omicron strains against the serum antibodies from 64 unvaccinated patients who had recovered from COVID-19 and the results were strongly correlated. The convalescent serum neutralization was more markedly reduced against the Omicron variant (9.4-57.9-fold) than the Delta variant (2.0-4.5-fold) as compared with the original strain. Our results demonstrate the reduced fusion and notable immune evasion capabilities of the Omicron variants, highlighting the importance of accelerating the development of vaccines targeting them.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 SerotherapyHumansImmune EvasionNeutralization TestsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID37178794
PMCPMC10200063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.